

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

Oxlumo (lumasiran)

PHYSICIAN INFORMATION			PATIENT INFORMATION			
* Physician Name: Specialty: * DEA, NPI or TIN:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*			
Office Contact Person:			* Patient Name:			
			* Cigna ID: * Date of Birth:			
Office Phone:						
Office Fax:			* Patient Street A	Address:		
Office Street Address:		_	City:	Sta	ate:	Zip:
City:	State:	Zip:	Patient Phone:			
Urgency: ☐ Standard	☐ Urg	ent (In checking this bo seriously jeopardize t				
Medication Requested:	Oxlumo 94.5	mg/0.5ml vial			ICD10:	
Directions for use: Dose: What is the patient's body weight?			Quantity:	Duration of therapy:		
Where will this medicate ☐ Orsini Specialty Pharm ☐ PANTHERx ☐ Retail pharmacy ☐ Other (please specify):	nacy	ed?		☐ Home F		nfusion vendor (billing on a medical
Facility and/or doctor Facility Name: Address (City, State, Zip C		d administering n State:	nedication:	Tax ID#:		
Where will this drug b ☐ Patient's Home	e administered	l?		☐ Physiciar	n's Office	
Hospital Outpatient			Other (please specify):			
NOTE : Per some	Cigna plans, infu	sion of medication M	UST occur in the	least intensiv	∕e, medically ap	propriate setting.
Is this patient a candidate assistance of a Specialty						ffice, home) with essity rationale):
Is the requested medication the patient?	on for a chronic or	long-term condition	for which the pre	scription med	lication may be	necessary for the life of Yes No
Clinical Information: **This drug require	s supportive d		art notes, gen quest**	etic test res	sults, etc.) be	attached with this
What is the diagnosis Primary Hyperoxaluria Primary Hyperoxaluria Primary Hyperoxaluria Other (please specify)	Type 1 (PH1) Type 2 (PH2) Type 3 (PH3)					
Will the patient use the re	quested drug con	currently with Rivfloz	a (nedosiran sub	cutaneous inj	jection)?	☐ Yes ☐ No

if yes or unknown) Please provide the rationale for concurrent use.						
Has the patient previously received a liver transplant for Primary Hyperoxaluria Type 1?	☐ Yes ☐ No					
Is this initial or is the patient currently receiving Oxlumo? ☐ Initial Therapy ☐ Currently Receiving Oxlumo						
if Currently Receiving Oxlumo) Is documentation being provided that the patient is continuing to derive benefit from Oxlumo, according to the prescriber? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims ecords, and/or other information. Medical documentation specific to your response to this question must be attached to this case or						
your request could be denied. Notes: Please Note: A "yes" answer must be reviewed by a member of the UMP/nurse team.	☐ Yes ☐ No					
(if no or unknown) Please provide support for continued use.						
(if Initial Therapy) Is documentation being provided that the patient has had a genetic test confirming the diagnosis of Hyperoxaluria Type 1 via identification of biallelic pathogenic variants in the alanine:glyoxylate aminotransferase gene Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or oth Medical documentation specific to your response to this question must be attached to this case or your request could Notes: Please Note: A "yes" answer must be reviewed by a member of the UMP/nurse team.	e (AGXT)? - ner information.					
(if Initial Therapy) Is documentation being provided that the patient has a urinary oxalate excretion of at least 0.5 mmol/24 hours/1.73 meters2 with the absence of secondary sources of oxalate? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied.						
Notes: Please Note: A "yes" answer must be reviewed by a member of the UMP/nurse team.	☐ Yes ☐ No					
(if no) Is documentation being provided that the patient has a urinary oxalate:creatinine ratio above the age-specific upp limit of normal? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims recand/or other information. Medical documentation specific to your response to this question must be attached to this case your request could be denied.						
Notes: Please Note: A "yes" answer must be reviewed by a member of the UMP/nurse team.	☐ Yes ☐ No					
(if no) Is documentation being provided that the patient has a plasma oxalate level at least 20 μmol/ note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records information. Medical documentation specific to your response to this question must be attached to t request could be denied.	, and/or other					
Notes: Please Note: A "yes" answer must be reviewed by a member of the UMP/nurse team.	☐ Yes ☐ No					
(if Initial Therapy) Is Oxlumo being prescribed by, or in consultation with, a nephrologist or urologist?	☐ Yes ☐ No					
Additional pertinent information (including prior therapy, disease stage, performance status, and names/doses/admany agents to be used concurrently):	nin schedule of					
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.						
Prescriber Signature: Date:						

 $Save\ Time!\ Submit\ Online\ at: \underline{www.covermymeds.com/main/prior-authorization-forms/cigna/}\ or\ via\ SureScripts\ in\ your\ EHR.$

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.